Skip to content
Inciteful Med

Building Your Care Team and Managing Long-Term Health

Last updated:

Mucopolysaccharidosis type 1 (MPS I) is a progressive disorder requiring a lifelong, coordinated team of specialists. Even after initial therapies, children need routine monitoring of their heart, bones, eyes, and airway to manage disease progression in hard-to-reach sanctuary sites.

Key Takeaways

  • • MPS I is a progressive disorder that requires lifelong monitoring even after initial treatments like stem cell transplants or enzyme replacement therapy.
  • • A multidisciplinary care team is essential, typically led by a metabolic geneticist and including cardiologists, orthopedists, and other specialists.
  • • Routine surveillance schedules should include regular echocardiograms, sleep studies, eye exams, and hearing tests to catch disease progression early.
  • • Children with MPS I face higher anesthesia and surgical risks due to unique airway and spine anatomy, requiring specialized surgical planning.

Once your child has completed their initial treatment—such as a stem cell transplant or starting enzyme replacement therapy—your focus will shift from “crisis mode” to long-term management. Because Mucopolysaccharidosis type 1 (MPS I) is a progressive, multisystem disorder, it requires a lifelong commitment to monitoring and coordinated care [1][2][3].

Why Lifelong Monitoring is Essential

Even with the most advanced treatments available today, some parts of the body are harder to reach than others. These “sanctuary sites” can continue to show disease progression despite successful initial therapy [4][5][6].

  • Heart Valves: The thick, dense tissue of heart valves is difficult for enzymes to penetrate [7][8]. This means that conditions like mitral stenosis (narrowing of a heart valve) may still progress and eventually require surgical intervention [7][9].
  • Bone and Spine: Bone disease, known as dysostosis multiplex, remains one of the greatest challenges in MPS I management [4][10]. Issues like hip dysplasia and spinal curvature (kyphosis) often require ongoing orthopedic care [11][12].
  • Eyes and Ears: Corneal clouding (hazy vision) and hearing loss are highly prevalent and may continue to change over time, requiring regular check-ups [13][14][15].

Building Your Multidisciplinary Team

Because MPS I affects so many different systems, you will need a team of specialists who communicate with one another [1][16][17]. Essential members of this team include:

  • Metabolic Geneticist: Often the “captain” of the team, managing the overall diagnosis and treatment plan [1][18].
  • Cardiologist: Monitors heart valve health and heart function through regular imaging [7][8].
  • Orthopedic Surgeon: Manages bone deformities, joint stiffness, and spine health [11][12].
  • Ophthalmologist: Checks for corneal clouding and increased pressure in the eye (glaucoma) [19][20].
  • Neurologist / Neurosurgeon: Monitors for hydrocephalus (fluid buildup in the brain) and potential spinal cord compression [21][22].
  • Pulmonologist / ENT: Manages airway issues, such as obstructive sleep apnea, and monitors hearing [3][23][14].

Routine Surveillance Schedule

While your doctor will tailor a plan to your child’s specific needs, the following evaluations are commonly recommended as part of a standard monitoring routine:

Evaluation Common Frequency What it Monitors
Echocardiogram Annual (or as needed) Heart valve thickening and function [7][8]
Sleep Study Annual (or as needed) Breathing quality and sleep apnea risks [23][24]
Eye Exam Annual Vision, corneal clouding, and eye pressure [19][20]
Hearing Test Every 6-12 months Conductive or mixed hearing loss [14][15]
Cervical Spine MRI Per specialist advice Spinal cord compression or neck instability [11][21]
Nerve Conduction Annual (age 3+) Silent carpal tunnel syndrome [25]

A Note on Surgical Safety

Children with MPS I face higher risks during surgery due to their unique airway and spine anatomy [10][23]. Always ensure that any surgeon or dentist you visit is aware of your child’s diagnosis, and whenever possible, work with an anesthesiologist who has experience with lysosomal storage disorders [10][26]. Your child’s metabolic team can provide a “surgical plan” to share with other providers to ensure safety during even minor procedures [1][10].

Frequently Asked Questions

Why does my child need lifelong monitoring for MPS I after treatment?
Even after successful treatments like stem cell transplants or enzyme replacement therapy, some areas of the body are harder for the therapy to reach. These 'sanctuary sites,' such as the heart valves, bones, and eyes, can continue to show disease progression and require ongoing specialized care.
Which specialists should be on my child's MPS I care team?
Because MPS I affects many different body systems, your team should be multidisciplinary. It typically includes a metabolic geneticist to coordinate overall care, alongside a cardiologist, orthopedic surgeon, ophthalmologist, neurologist, and pulmonologist or ENT.
What routine tests are needed to monitor MPS I progression?
Standard monitoring usually involves annual echocardiograms to check heart valves, sleep studies to monitor breathing, eye and hearing exams, and specific imaging like cervical spine MRIs to check for spinal cord compression. Your metabolic team will tailor this schedule to your child.
Are there special risks for children with MPS I during surgery?
Yes, children with MPS I face higher risks during surgery and anesthesia due to their unique airway and spine anatomy. It is crucial to work with an anesthesiologist experienced in lysosomal storage disorders and to share a dedicated surgical plan from your metabolic team with all providers.

Questions for Your Doctor

  • • Who will be the primary 'coordinator' of my child's multidisciplinary team?
  • • How often should we schedule 'baseline' and follow-up echocardiograms to monitor heart valve changes?
  • • What specific signs of spinal cord compression or cervical instability should I look for at home?
  • • Are there any specific orthopedic surgeries we should anticipate in the next few years?
  • • How do we handle the higher risks of anesthesia if my child needs a procedure like ear tubes or a hernia repair?
  • • Is my child's airway considered safe for this upcoming procedure?

Questions for You

  • • How has my child's mobility or joint stiffness changed since their last specialist visit?
  • • Have I noticed any changes in my child's breathing or snoring during sleep?
  • • Are there any new 'fine motor' struggles, such as difficulty with buttons or zippers, that could indicate carpal tunnel syndrome?
  • • Which specialists have we seen in the last year, and are their reports being shared with our central metabolic team?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Mucopolysaccharidosis Type I in Mexico: Case-Based Review.

    Cantú-Reyna C, Vazquez-Cantu DL, Cruz-Camino H, et al.

    Children (Basel, Switzerland) 2023; (10(4)) doi:10.3390/children10040642.

    PMID: 37189891
  2. 2

    Implementation of an Affordable Method for MPS Diagnosis from Urine Screening to Enzymatic Confirmation: Results of a Pilot Study in Morocco.

    Fdil N, Sabir ES, Ezoubeiri A, et al.

    Clinical laboratory 2020; (66(3)) doi:10.7754/Clin.Lab.2019.190720.

    PMID: 32162878
  3. 3

    Long-term evolution of mucopolysaccharidosis type I in twins treated with enzyme replacement therapy plus hematopoietic stem cells transplantation.

    Carbajal-Rodríguez LM, Pérez-García M, Rodríguez-Herrera R, et al.

    Heliyon 2021; (7(8)):e07740 doi:10.1016/j.heliyon.2021.e07740.

    PMID: 34458603
  4. 4

    MPS I: Early diagnosis, bone disease and treatment, where are we now?

    Kingma SDK, Jonckheere AI

    Journal of inherited metabolic disease 2021; (44(6)):1289-1310 doi:10.1002/jimd.12431.

    PMID: 34480380
  5. 5

    Progression of Hip Dysplasia in Mucopolysaccharidosis Type I Hurler After Successful Hematopoietic Stem Cell Transplantation.

    Langereis EJ, den Os MM, Breen C, et al.

    The Journal of bone and joint surgery. American volume 2016; (98(5)):386-95 doi:10.2106/JBJS.O.00601.

    PMID: 26935461
  6. 6

    Neonatal combination therapy improves some of the clinical manifestations in the Mucopolysaccharidosis type I murine model.

    Santi L, De Ponti G, Dina G, et al.

    Molecular genetics and metabolism 2020; (130(3)):197-208 doi:10.1016/j.ymgme.2020.05.001.

    PMID: 32439268
  7. 7

    Residual glycosaminoglycan accumulation in mitral and aortic valves of a patient with attenuated MPS I (Scheie syndrome) after 6 years of enzyme replacement therapy: Implications for early diagnosis and therapy.

    Sato Y, Fujiwara M, Kobayashi H, et al.

    Molecular genetics and metabolism reports 2015; (5()):94-97 doi:10.1016/j.ymgmr.2015.10.014.

    PMID: 28649551
  8. 8

    Cardiac manifestations and effects of enzyme replacement therapy for over 10 years in adults with the attenuated form of mucopolysaccharidosis type I.

    Sugiura K, Kubo T, Ochi Y, et al.

    Molecular genetics and metabolism reports 2020; (25()):100662 doi:10.1016/j.ymgmr.2020.100662.

    PMID: 33101981
  9. 9

    Urgent resection of a giant left atrial appendage aneurysm and mitral valve replacement in a complex case of Hurler-Scheie syndrome.

    Brazier A, Hasan R, Jenkins P, Hoschtitzky A

    BMJ case reports 2015; (2015()).

    PMID: 26546621
  10. 10

    Enzyme replacement therapy with laronidase (Aldurazyme®) for treating mucopolysaccharidosis type I.

    Jameson E, Jones S, Remmington T

    The Cochrane database of systematic reviews 2019; (6()):CD009354 doi:10.1002/14651858.CD009354.pub5.

    PMID: 31211405
  11. 11

    Chiari I malformation and syringomyelia in mucopolysaccharidosis type I (Hurler syndrome) treated with posterior fossa decompression: Case report and review of the literature.

    Makler V, Goldstein CL, Hoernschemeyer D, Tanaka T

    Surgical neurology international 2017; (8()):80 doi:10.4103/sni.sni_463_16.

    PMID: 28607814
  12. 12

    Mucopolysaccharidosis type I due to maternal uniparental disomy of chromosome 4 with partial isodisomy of 4p16.3p15.2.

    Katja K, Inga V, Ramona L, et al.

    Molecular genetics and metabolism reports 2020; (25()):100660 doi:10.1016/j.ymgmr.2020.100660.

    PMID: 33117653
  13. 13

    Progressive eye pathology in mucopolysaccharidosis type I mice and effects of enzyme replacement therapy.

    Gonzalez EA, Visioli F, Pasqualim G, et al.

    Clinical & experimental ophthalmology 2020; (48(3)):334-342 doi:10.1111/ceo.13713.

    PMID: 31925897
  14. 14

    Audiometric evaluation in individuals with mucopolysaccharidosis.

    Silveira MRMD, Buriti AKL, Martins AM, et al.

    Clinics (Sao Paulo, Brazil) 2018; (73()):e523 doi:10.6061/clinics/2018/e523.

    PMID: 30517303
  15. 15

    Hurler-Scheie syndrome in Niger: a case series.

    Assadeck H, Toudou Daouda M, Bako H, Hassane Djibo F

    Journal of medical case reports 2019; (13(1)):102 doi:10.1186/s13256-019-2047-2.

    PMID: 31018863
  16. 16

    Multidisciplinary Team Approach Is Key for Managing Pregnancy and Delivery in Patient with Rare, Complex MPS I.

    Troko J, Poonawala Y, Geberhiwot T, Martin B

    JIMD reports 2016; (30()):1-5 doi:10.1007/8904_2016_527.

    PMID: 26920904
  17. 17

    Intracranial tumor in a patient with mucopolysaccharidosis type 1 (Scheie syndrome): An extremely rare combination.

    Kukreja S, Soomro AI, Lohana S, et al.

    Heliyon 2024; (10(19)):e38652 doi:10.1016/j.heliyon.2024.e38652.

    PMID: 39397911
  18. 18

    Genotype-phenotype relationships in mucopolysaccharidosis type I (MPS I): Insights from the International MPS I Registry.

    Clarke LA, Giugliani R, Guffon N, et al.

    Clinical genetics 2019; (96(4)):281-289 doi:10.1111/cge.13583.

    PMID: 31194252
  19. 19

    Ocular Manifestations of Hurler-Scheie Syndrome: Recurrence of Host Disease in the Corneal Transplant.

    Kölkedi Z, Csutak A, Szalai E

    Molecular syndromology 2023; (14(1)):44-50 doi:10.1159/000525453.

    PMID: 36777710
  20. 20

    Deep Anterior Lamellar Keratoplasty in a Case of Hurler-Scheie Syndrome Undergoing Enzyme Replacement Therapy.

    Eah KS, Lee CM, Kim MJ

    Cornea 2019; (38(3)):376-378 doi:10.1097/ICO.0000000000001840.

    PMID: 30575621
  21. 21

    Neuroimaging and spinal manifestations of mucopolysaccharidosis type I: Insights from a pediatric case.

    Boujida N, Jabour S, Elaitari K, et al.

    Radiology case reports 2025; (20(12)):5795-5799 doi:10.1016/j.radcr.2025.08.011.

    PMID: 40989062
  22. 22

    Markedly Elevated Intracranial Pressure Treated With Cranial Vault Expansion, Instead of CSF Shunting, in a Child With Hurler-Scheie Syndrome and Multiple Suture Craniosynostosis.

    Ching JA, Troy JS, Ruas EJ, et al.

    The Cleft palate-craniofacial journal : official publication of the American Cleft Palate-Craniofacial Association 2019; (56(3)):395-399 doi:10.1177/1055665618777906.

    PMID: 29791186
  23. 23

    Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I.

    Jameson E, Jones S, Remmington T

    The Cochrane database of systematic reviews 2016; (4()):CD009354 doi:10.1002/14651858.CD009354.pub4.

    PMID: 27033167
  24. 24

    Safety and efficacy of laronidase in Chinese patients with mucopolysaccharidosis type I: a phase IV, single-arm, open-label, multicenter study.

    Liang Y, Yang YL, Zou CC, et al.

    Orphanet journal of rare diseases 2025; (20(1)):547 doi:10.1186/s13023-025-04056-w.

    PMID: 41163043
  25. 25

    Carpal tunnel syndrome in mucopolysaccharidosis I: a registry-based cohort study.

    Viskochil D, Muenzer J, Guffon N, et al.

    Developmental medicine and child neurology 2017; (59(12)):1269-1275 doi:10.1111/dmcn.13545.

    PMID: 28892147
  26. 26

    Identification of a novel compound heterozygous IDUA mutation underlies Mucopolysaccharidoses type I in a Chinese pedigree.

    Zhou YA, Li P, Zhang Y, et al.

    Molecular genetics & genomic medicine 2020; (8(1)):e1058 doi:10.1002/mgg3.1058.

    PMID: 31758674

This page is for informational purposes only and does not replace professional medical advice. Always consult your child's metabolic team and specialists regarding specific long-term care, monitoring, and surgical risks.

Stay up to date

Get notified when new research about Mucopolysaccharidosis type 1 is published.

No spam. Unsubscribe anytime.